Clinical Trial Update: Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a tumor vaccine in combination with interferon gamma for patients with refractory epithelial ovarian cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Interferon-gamma (interferon gamma)
• Tumor vaccine (tumor vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ovarian Epithelial Cancer | Phase 1 | Status: COMPLETED